Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Inclusion/Exclusion Criteria
2.2. Endpoints
2.3. Treatment Procedure
2.4. Statistics
3. Results
3.1. Patients
3.2. Treatment
3.3. Toxicity
3.4. Aesthetic Assessment
3.5. Quality of Life
3.6. Survival
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
References
- Schubert, L.K.; Gondi, V.; Sengbusch, E.; Westerly, D.C.; Soisson, E.T.; Paliwal, B.; Mackie, T.R.; Mehta, M.P.; Patel, R.R.; Tomé, W.A.; et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother. Oncol. 2011, 100, 241–246. [Google Scholar] [CrossRef] [PubMed]
- Donovan, E.; Bleakley, N.; Denholm, E.; Evans, P.; Gothard, L.; Hanson, J.; Peckitt, C.; Reise, S.; Ross, G.; Sharp, G.; et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother. Oncol. 2007, 82, 254–264. [Google Scholar] [CrossRef] [PubMed]
- Mukesh, M.; Barnett, G.C.; Wilkinson, J.S.; Moody, A.M.; Wilson, C.; Dorling, L.; Hak, C.C.W.; Qian, W.; Twyman, N.; Burnet, N.G.; et al. Randomized Controlled Trial of Intensity-Modulated Radiotherapy for Early Breast Cancer: 5-Year Results Confirm Superior Overall Cosmesis. J. Clin. Oncol. 2013, 31, 4488–4495. [Google Scholar] [CrossRef] [PubMed]
- Pignol, J.-P.; Truong, P.; Rakovitch, E.; Sattler, M.G.; Whelan, T.J.; Olivotto, I.A. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. Radiother. Oncol. 2016, 121, 414–419. [Google Scholar] [CrossRef]
- Krueger, E.A.; Fraass, B.A.; McShan, D.L.; Marsh, R.; Pierce, L.J. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int. J. Radiat. Oncol. 2003, 56, 1023–1037. [Google Scholar] [CrossRef]
- Caudrelier, J.-M.; Morgan, S.C.; Montgomery, L.; Lacelle, M.; Nyiri, B.; MacPherson, M. Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: Dosimetric evaluation. Radiother. Oncol. 2009, 90, 99–105. [Google Scholar] [CrossRef]
- Haviland, J.S.; Owen, J.R.; Dewar, J.A.; Agrawal, R.K.; Barrett, J.M.; Barrett-Lee, P.J.; Dobbs, H.J.; Hopwood, P.; Lawton, P.A.; Magee, B.J.; et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013, 14, 1086–1094. [Google Scholar] [CrossRef]
- Sedlmayer, F.; Sautter-Bihl, M.; Budach, W.; Dunst, J.; Feyer, P.; Fietkau, R.; Haase, W.; Harms, W.; Rodel, C.; Souchon, R.; et al. Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy? Strahlenther. Onkol. 2013, 189, 193–196. [Google Scholar] [CrossRef] [Green Version]
- Dewan, A.; Chufal, K.S.; Dewan, A.K.; Pahuja, A.; Mehrotra, K.; Singh, R.; Chaudhary, R.L.; Suresh, T.; Mishra, M.; Sundari, A.V.; et al. Simultaneous integrated boost by Intensity Modulated Radiotherapy (SIB-IMRT) in patients undergoing breast conserving surgery—A clinical and dosimetric perspective. J. Egypt. Natl. Cancer Inst. 2018, 30, 165–171. [Google Scholar] [CrossRef]
- Qiao, X.; Song, Y.; Zhen, C.; Li, J.; Liu, M.; Zhou, Z.; Wang, Y.; Zhang, X. Simultaneous Integrated Boost Intensity Modulated Radiation Therapy in Early Breast Cancer Patients After Breast Conserving Surgery: A Prospective Study. Int. J. Radiat. Oncol. 2015, 93, e5. [Google Scholar] [CrossRef]
- Coles, C.; Griffin, C.; Kirby, A.; Haviland, J.; Titley, J.; Benstead, K.; Brunt, A.; Chan, C.; Ciurlionis, L.; Din, O.; et al. Abstract GS4-05: Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Gen. Sess. Abstr. 2019, 79, GS4-05. [Google Scholar] [CrossRef]
- Crop, F.; Pasquier, D.; Baczkiewic, A.; Doré, J.; Bequet, L.; Steux, E.; Gadroy, A.; Bouillon, J.; Florence, C.; Muszynski, L.; et al. Surface imaging, laser positioning or volumetric imaging for breast cancer with nodal involvement treated by helical TomoTherapy. J. Appl. Clin. Med. Phys. 2016, 17, 200–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crop, F.; Heckel, R.; Pasquier, D.; Lartigau, E.; Reynaert, N. EP-1617: Optimal skin retraction for Helical Tomotherapy breast planning ñ robustness vs skin dose. Radiother. Oncol. 2014, 111, S211. [Google Scholar] [CrossRef]
- Pasquier, D.; Le Tinier, F.; Bennadji, R.; Jouin, A.; Horn, S.; Escande, A.; Tresch, E.; Chauvet, M.P.; Mailliez, A.; Crop, F.; et al. Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: A prospective study on toxicity and quality of life. Sci. Rep. 2019, 9, 2759. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Offersen, B.V.; Boersma, L.J.; Kirkove, C.; Hol, S.; Aznar, M.C.; Sola, A.B.; Kirova, Y.; Pignol, J.-P.; Remouchamps, V.; Verhoeven, K.; et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother. Oncol. 2015, 114, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Li, X.A.; Tai, A.; Arthur, D.W.; Buchholz, T.A.; Macdonald, S.; Marks, L.B.; Moran, J.M.; Pierce, L.J.; Rabinovitch, R.; Taghian, A.; et al. Variability of Target and Normal Structure Delineation for Breast Cancer Radiotherapy: An RTOG Multi-Institutional and Multiobserver Study. Int. J. Radiat. Oncol. 2009, 73, 944–951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McDonald, M.W.; Godette, K.D.; Whitaker, D.J.; Davis, L.W.; Johnstone, P.A. Three-Year Outcomes of Breast Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost. Int. J. Radiat. Oncol. 2010, 77, 523–530. [Google Scholar] [CrossRef]
- Franco, P.; Zeverino, M.; Migliaccio, F.; Sciacero, P.; Cante, D.; Borca, V.C.; Torielli, P.; Arrichiello, C.; Girelli, G.; Numico, G.; et al. Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): A prospective case series. J. Cancer Res. Clin. Oncol. 2013, 139, 1927–1936. [Google Scholar] [CrossRef]
- Liem, X.; Chira, C.; Fourquet, A.; Campana, F.; Peurien, D.; Fournier-Bidoz, N.; Kirova, Y. Résultats préliminaires d’une tomothérapie hélicoïdale adjuvante avec boost intégré dans le cadre d’un traitement conservateur d’un cancer du sein. Cancer/Radiothérapie 2014, 18, 15–22. [Google Scholar] [CrossRef]
- Fiorentino, A.; Mazzola, R.; Ricchetti, F.; Levra, N.G.; Fersino, S.; Naccarato, S.; Sicignano, G.; Ruggieri, R.; Di Paola, G.; Massocco, A.; et al. Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer/Radiothérapie 2015, 19, 289–294. [Google Scholar] [CrossRef]
- Aoulad, N.; Massabeau, C.; De Lafontan, B.; Vieillevigne, L.; Hangard, G.; Ciprian, C.; Chaltiel, L.; Moyal, É.; Izar, F. Toxicité aiguë de la tomothérapie des cancers mammaires. Cancer/Radiothérapie 2017, 21, 180–189. [Google Scholar] [CrossRef] [PubMed]
- Freedman, G.M.; Anderson, P.R.; Li, J.; Eisenberg, D.F.; Hanlon, A.L.; Wang, L.; Nicolaou, N. Intensity Modulated Radiation Therapy (IMRT) Decreases Acute Skin Toxicity for Women Receiving Radiation for Breast Cancer. Am. J. Clin. Oncol. 2006, 29, 66–70. [Google Scholar] [CrossRef] [PubMed]
- Sas-Korczynska, B.; Śladowska, A.; Rozwadowska-Bogusz, B.; Dyczek, S.; Lesiak, J.; Kokoszka, A.; Korzeniowski, S. Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy. Rep. Pract. Oncol. Radiother. 2010, 15, 79–86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bourgier, C.; Lacombe, J.; Solassol, J.; Mangé, A.; Pèlegrin, A.; Ozsahin, M.; Azria, D. Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Crit. Rev. Oncol. 2015, 93, 312–319. [Google Scholar] [CrossRef] [PubMed]
- Straub, J.M.; New, J.; Hamilton, C.D.; Lominska, C.; Shnayder, Y.; Thomas, S.M. Radiation-induced fibrosis: Mechanisms and implications for therapy. J. Cancer Res. Clin. Oncol. 2015, 141, 1985–1994. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bantema-Joppe, E.J.; Schilstra, C.; De Bock, G.H.; Dolsma, W.V.; Busz, D.M.; Langendijk, J.A.; Maduro, J. Simultaneous Integrated Boost Irradiation After Breast-Conserving Surgery: Physician-Rated Toxicity and Cosmetic Outcome at 30 Months’ Follow-Up. Int. J. Radiat. Oncol. 2012, 83, e471–e477. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.-H.; Hou, M.-F.; Chuang, H.-Y.; Huang, M.-Y.; Tsuei, L.-P.; Chen, F.-M.; Yang, F.Q.; Huang, C.-J. Intensity modulated radiotherapy with simultaneous integrated boost vs. conventional radiotherapy with sequential boost for breast cancer—A preliminary result. Breast 2015, 24, 656–660. [Google Scholar] [CrossRef]
- Sura, K.; Tan, K.; Freedman, G.; Troxel, A.; Lin, L. Factors Affecting Breast Cancer Patient Quality of Life in Association with Radiation. Int. J. Radiat. Oncol. 2013, 87, S115–S116. [Google Scholar] [CrossRef]
- Daldoul, A.; Khechine, W.; Bhiri, H.; Ammar, N.; Bouriga, R.; Krir, M.W.; Soltani, S.; Zoukar, O.; Rhim, M.S.; Bouslah, S.; et al. Factors Predictive of Quality of Life among Breast Cancer Patients. Asian Pac. J. Cancer Prev. 2018, 19, 1671–1675. [Google Scholar]
- Mukesh, M.B.; Qian, W.; Wilkinson, J.S.; Dorling, L.; Barnett, G.C.; Moody, A.M.; Wilson, C.; Twyman, N.; Burnet, N.G.; Wishart, G.C.; et al. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: Results from the Cambridge Breast IMRT trial. Radiother. Oncol. 2014, 111, 270–275. [Google Scholar] [CrossRef]
- Kindts, I.; Laenen, A.; Akker, M.V.D.; Weltens, C. PROMs following breast-conserving therapy for breast cancer: Results from a prospective longitudinal monocentric study. Support. Care Cancer 2019, 27, 4123–4132. [Google Scholar] [CrossRef] [PubMed]
- Abo-Madyan, Y.; Aziz, M.H.; Aly, M.M.; Schneider, F.; Sperk, E.; Clausen, S.; Giordano, F.A.; Herskind, C.; Steil, V.; Wenz, F.; et al. Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. Radiother. Oncol. 2014, 110, 471–476. [Google Scholar] [CrossRef] [PubMed]
- Grantzau, T.; Thomsen, M.S.; Væth, M.; Overgaard, J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother. Oncol. 2014, 111, 366–373. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Number (%) | Median (Min–Max) |
---|---|---|
Age | 55 (32–82) | |
Smoking | 79 (27.4%) | |
Cardiac disease | 94 (23.8%) | |
Diabetes | 43 (14.9%) | |
Dyslipidemia | 91 (28.3%) | |
Respiratory disease | 29 (10.1%) | |
BMI (Kg/m2) | 26.5 (16.5–48.8) | |
Normal | 111 (38.8%) | |
Overweight (≥25) | 95 (33.2%) | |
Obese (≥30) | 80 (28%) | |
WHO score | ||
0 | 222 (79%) | |
1 | 58 (20.6%) | |
2 | 1 (0.4%) | |
Breast size | ||
Small (85A-B, 90A) | 31 (11.6%) | |
Medium (85C, 90B-C, 95A-B) | 76 (28.4%) | |
Big (>85C, >90C, >95B) | 161 (60.1%) | |
Breast side | ||
Left | 140 (48.6%) | |
Right | 132 (45.8%) | |
Bilateral | 16 (5.6%) | |
Size (mm) | ||
Clinical | 30 (0–300) | |
Imaging | 24 (3–80) | |
Tumor stage | ||
pT0 | 23 (8%) | |
pT1 | 122 (42.4%) | |
pT2 | 110 (38.2%) | |
pT3 | 30 (10.4%) | |
pT4 | 3 (1%) | |
Nodal status | ||
pN0 | 60 (20.8%) | |
pN1-3 | 215 (74.7%) | |
pNx | 13 (4.5%) | |
Histology | ||
Invasive ductal carcinoma | 217 | 75.4% |
Invasive lobular carcinoma | 33 | 11.4% |
Other | 38 | 13.2% |
In situ component (N = 281) | 116 | 41.3% |
SBR (N = 264) | ||
SBR I | 64 | 24.2% |
SBR II | 143 | 54.2% |
SBR III | 57 | 21.6% |
Lymphovascular space involvement (N = 247) | 77 | 31.2% |
ER+ (N = 286) | 243 | 85.0% |
PR+ (N = 286) | 205 | 71.7% |
HER2+++ (N = 273) | 42 | 15.4% |
Triple negative (N = 288) | 28 | 9.7% |
Heading | D2%: Median (Min–Max) | D50% | D98% |
---|---|---|---|
PTV breast (including boost) | 61.3 (50.6–63.4) | 50 (44.7–51.4) | 46 (40.2–49.7) |
PTV internal mammary chain | 52.3 (46.8–59.6) | 49.8 (44.4–51.1) | 46.5 (10.6–49) |
PTV supraclavicular (area 1 optional, area 2) | 52 (46.5–54.3) | 49.8 (44.6–51.3) | 46.2 (41.9–49.4) |
PTV infraclavicular (areas 3–5) | 52.0 (46.5–55.2) | 49.8 (44.8–51) | 46.3 (39–49.6) |
Organ at Risk | Dosimetric Parameters | ||
---|---|---|---|
Spinal cord | Dmean: 4.7 (1.8) | D2%: 14.8 (5.5) | |
Esophagus | Dmean: 11.4 (4.3) | V30: 9.5 (8.9) | V45: 1.2 (2.5) |
Heart (left breast) | Dmean: 7.8 (3) | V15: 11.3 (7) | V40: 0.5 (0.6) |
Ipsilateral lung | Dmean: 13.5 (2.7) | V20: 24.1 (7) | V30: 14 (4.8) |
Contralateral lung | Dmean: 4.8 (1.6) | V15: 1.9 (2.3) | V20: 0.5 (0.9) |
Contralateral breast | Dmean: 3.8 (1.4) |
Toxicity | Acute: Number (%) | Medium-Term: Number (%) |
---|---|---|
Skin reaction | 278 (96.5%) | 152 (53.1%) |
Grade 1 | 172 (59.7%) | 147 (51.0%) |
Grade 2 | 102 (35.4%) | 2 (0.6%) |
Grade 3 | 4 (1.4%) | 2 (0.6%) |
Unknown grade | 0 | 1 (0.3%) |
Esophagitis | 138 (47.9%) | 6 (2.1%) |
Grade 1 | 120 (41.7%) | 6 (2.1%) |
Grade 2 | 18 (6.3%) | 0 |
Breast fibrosis (N = 168) | N/A | 68 (40.7%) |
Grade 1 | N/A | 59 (35.3%) |
Grade 2 | N/A | 9 (5.4%) |
Chest wall fibrosis (N = 120) | N/A | 51 (42.9%) |
Grade 1 | N/A | 42 (35.3%) |
Grade 2 | N/A | 9 (7.6%) |
Tumor bed fibrosis (N = 168) | 31 (18.8%) | 66 (39.5%) |
Grade 1 | 29 (17.6%) | 56 (33.5%) |
Grade 2 | 1 (0.6%) | 10 (6.0%) |
Unknown grade | 1 (0.6%) | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bataille, B.; Raoudha, B.; Le Tinier, F.; Basson, L.; Escande, A.; Langin, H.; Tresch, E.; Crop, F.; Darloy, F.; Carlier, D.; et al. Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer. Cancers 2020, 12, 3852. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123852
Bataille B, Raoudha B, Le Tinier F, Basson L, Escande A, Langin H, Tresch E, Crop F, Darloy F, Carlier D, et al. Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer. Cancers. 2020; 12(12):3852. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123852
Chicago/Turabian StyleBataille, Benoît, Bennadji Raoudha, Florence Le Tinier, Laurent Basson, Alexandre Escande, Hélène Langin, Emmanuelle Tresch, Frederik Crop, Franck Darloy, Damien Carlier, and et al. 2020. "Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer" Cancers 12, no. 12: 3852. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123852